MedTrace Logo

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

NCT02047461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-10-17

Study results available
· View outcomes & findings →

Summary

This study will include a screening period, a 6-month treatment period, followed by long-term extension period expected to last approximately 72 months.

Conditions

  • Molybdenum Cofactor Deficiency, Type A

Interventions

DRUG

ORGN001 (formerly ALXN1101)

IV infusion

Sponsors & Collaborators

  • Origin Biosciences

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2022-08-31
Completion
2022-10-31

Countries

  • United States
  • Australia
  • Netherlands
  • Tunisia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02047461 on ClinicalTrials.gov